Skip to main content

Table 4 Outcomes metastatic melanoma

From: Clinical characteristics and treatment-related biomarkers associated with response to high-dose interleukin-2 in metastatic melanoma and renal cell carcinoma: retrospective analysis of an academic community hospital’s experience

  Clinical benefit (n=8) No clinical benefit (n=29) p-value
Total Doses 33.0 (29.0 – 41.75) 18.0 (12.5 – 28.0) .001*
Total Cycles 6.0 (5.0 – 6.0) 2.0 (2.0 – 4.0) <.001*
Doses per Cycle 6.4 (5.33 – 6.96) 7.0 (5.42 – 7.38) .502*
Duration (months) 26.0 (18.25 – 56.25) 1.0 (0 – 4.0) <.001*
Peak Fever (Celsius) 39.7 (38.5 – 40.3) 39.1 (38.4 – 39.3) .158*
Peak ALC 3.75 (2.85 – 5.425) 2.9 (1.9 – 4.05) .137*
Platelets 50.0 (37.25 – 93.0) 80.0 (69.5 – 133.0) .015*
Autoimmune phenomenon 4 (50.0%) 4 (13.8%) .049
Any Toxicity 5 (62.5%) 9 (31.0%) .215
None 3 (37.5%) 20 (68.9%) .215
Grade 3 3 (37.5%) 3 (10.3%) .101
Grade 4 2 (25.0%) 6 (20.7%) .1.0
Grade 5 -- -- --
Survived 6 (75.0%) 7 (24.1%) .006
Survival Months 61.0 17.0 .001¥
  1. Fisher’s Exact test (reported as frequency (percent)).
  2. *Mann–Whitney U (reported as median (interquartile range)).
  3. ¥Log-Rank Test (reported as median, censored data included).
  4. ALC: Absolute Lymphocyte Count.